GeneScience Pharmaceuticals International Pharmaceutical Industrial Park is currently under construction in Changchun, Northeast China's Jilin province, reports Changchun Daily.

The industrial park, developed by GeneScience Pharmaceuticals Co, is a provincial and municipal key construction project.

After the industrial park project reaches full production capacity, it is expected to generate an annual output of 30 billion yuan ($4.7 billion) and provide more than 2,000 jobs.

As the only national 11th Five-Year Plan (2006-10) genetic engineering pharmaceutical incubation base in the country and the largest genetic engineering pharmaceutical company in China, GeneScience Pharmaceuticals Co has always focused on technological innovation and new product research and development.

The company currently has a 500-person R&D team with 15 PhDs serving as the backbone, and it invests 10 percent of its sales annually in new product research and development, focusing on fields such as growth, reproduction, anti-aging, Alzheimer's disease, and tumors.

As one of the leading industries to be developed during the 14th Five-Year Plan period (2021-25), Changchun is striving to develop a pharmaceutical and health industrial cluster with an annual output of over 100 billion yuan by 2025.